Systemic Lupus Erythematosus

ISBN-13: 9780128205839 / Angielski / Twarda / 2021

Robert G. Lahita

Spis treści

Part I: Basis of the Disease Section A: Genetics and epigenetics 1. Major histocompatibility complex and SLE 2. Lupus Susceptibility genes 3. Epigenetics in systemic lupus erythematosus and the integration of molecular pathways

Section B: Immunopathogenesis 4. Autoantigens, antigenic mimicry, and immune complexes 5. B-cell Biology, tolerance and autoantibodies 6. T-Cell Biology, tolerance and regulation 7. Polymorphonuclear cells 8. Metabolic and mitochondrial dysfunction in SLE 9. Immunopathogenesis: the role of mucosal and skin microbiota in SLE

Section C: Disease effectors and modifiers 10. Complement and SLE 11. Interferons and cytokines in SLE pathogenesis and therapy 12. Innate immunity in SLE pathogenesis 13. Sex bias in SLE

Section D: Tissue injury-the Biology 14. Mechanisms of tissue injury in lupus nephritis 15. The skin 16. The brain in SLE: mechanisms and detection of injury and therapeutic strategies 17. The role of infections in SLE pathogenesis 18. Tissue injurydthe biology: SLE-associated vascular disease and antiphospholipid syndrome

Part II: Clinical presentation of disease Section A: Clinical presentation 19. Epidemiology of SLE and related diseases: incidence, prevalence, and mortality 20. The clinical presentation of systemic lupus erythematosus and laboratory diagnosis 21. Passively acquired lupus in the fetus and neonate 22. Systemic lupus erythematosus in children 23. Environmental and drug-induced lupus 24. Reproductive health 25. Monitoring disease activity 26. Overlap syndromes

Section B: Specific organ involvement and clinical presentation 27. Nervous system 28. Skin 29. Kidney disease 30. Cardiovascular disease in lupus 31. Pulmonary manifestations of systemic lupus erythematosus 32. GI hepatic and nonhepatic diseases 33. Musculoskeletal system: articular disease, myositis, and bone metabolism 34. Clinical presentation of antiphospholipid syndrome 35. Hematology: cytopenias 36. Malignancy risk and screening

Section C: Treatment of systemic llupus erythematosus 37. Antimalarial drugs (and lupus) 38. Glucocorticoids 39. Immunosuppressive therapy in SLE 40. Pipeline therapies and future drug development 41. Challenges of systemic lupus clinical trials